- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| Di | Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) | 1 | GlobeNewswire (USA) | ||
| Fr | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.06. | Longeveron to Present at BIO International Convention 2026 | 17 | GlobeNewswire (USA) | ||
| 20.05. | Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities | 116 | GlobeNewswire (Europe) | MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related... ► Artikel lesen | |
| 14.05. | Longeveron anticipates August 2026 ELPIS II readout while shifting to an asset-light partnering model | 2 | Seeking Alpha | ||
| 13.05. | Longeveron Q1 2026 Earnings Call: Complete Transcript | 1 | Benzinga.com | ||
| 13.05. | Longeveron GAAP EPS of -$0.19 misses by $0.02, revenue of $0.4M beats by $0.08M | 1 | Seeking Alpha | ||
| 13.05. | Longeveron Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.05. | Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS) | 5 | GlobeNewswire (USA) | ||
| 08.05. | Longeveron erleidet Rückschlag: FDA stuft HLHS-Studie nicht mehr als zulassungsrelevant ein | 2 | Investing.com Deutsch | ||
| 08.05. | Longeveron faces setback as FDA no longer views HLHS trial as pivotal | 1 | Investing.com | ||
| 08.05. | Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) | 306 | GlobeNewswire (Europe) | MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic... ► Artikel lesen | |
| 08.05. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.05. | H.C. Wainwright cuts Longeveron stock price target on dilution | 2 | Investing.com | ||
| 10.04. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | Longeveron Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 08.04. | Longeveron receives China patent for stem cell potency assay | 5 | Investing.com | ||
| 08.04. | Longeveron erhält chinesisches Patent für Testverfahren von Stammzellen | 1 | Investing.com Deutsch | ||
| 08.04. | Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) | 1 | GlobeNewswire (USA) | ||
| 24.03. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 43,985 | +2,72 % | Morgan Stanley assumes CRISPR Therapeutics stock with equalweight rating | ||
| OCUGEN | 1,102 | +6,37 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| EDITAS MEDICINE | 2,180 | +1,40 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,202 | +1,61 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
| DENALI THERAPEUTICS | 18,580 | +4,00 % | Denali Therapeutics Inc. - 8-K, Current Report | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Appointment of Davidson & Company as Its New Auditor | Toronto, Ontario--(Newsfile Corp. - May 22, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), is pleased to announce the appointment of Davidson... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,650 | +1,54 % | H.C. Wainwright reiterates Fate Therapeutics stock rating on SLE data | ||
| TRINITY BIOTECH | 0,680 | -1,08 % | TRINITY BIOTECH PLC - 6-K, Report of foreign issuer | ||
| VOYAGER THERAPEUTICS | 2,998 | +4,02 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| ARCTURUS THERAPEUTICS | 6,890 | 0,00 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| ANAVEX LIFE SCIENCES | 2,391 | +11,94 % | ANAVEX LIFE SCIENCES CORP im neutralen Takt | ||
| BIOAGE LABS | 13,710 | +2,24 % | BioAge Labs, Inc.: BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates | Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept... ► Artikel lesen | |
| CERUS | 2,240 | +0,90 % | Cerus Corporation Secures Up To $110 Million Debt Facility To Lower Borrowing Costs And Support Growth | ||
| LINEAGE CELL THERAPEUTICS | 1,042 | -2,62 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| OVID THERAPEUTICS | 2,080 | +5,58 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors | NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,013 (+1,64 %) liegt der Kurs bei 0,783 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.